Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684694 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT03684694 is a Phase 1 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 136 participants.
The verdict
NCT03684694, a Phase 1 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
Interventions
- DRUG Loncastuximab Tesirine
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03684694
The ClinicalTrials.gov registry entry for NCT03684694 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loncastuximab Tesirine is the first listed.
NCT03684694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03684694 about?
NCT03684694 is a clinical study titled "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma". The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
What is the current status of trial NCT03684694?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2018-12-01. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT03684694?
The interventions under investigation include: Loncastuximab Tesirine (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03684694?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.